Healthcare remains one of the most structurally durable sectors in the global economy, but not all healthcare ETFs are built the same way. Comparing IXJ and PPH illustrates the difference between owning the entire healthcare complex and making a targeted, concentrated bet on pharmaceutical makers. These two funds do not compete directly; instead, they represent alternative approaches to similar investor goals. This ETF comparison examines sector exposure, structural characteristics, cost, and relative positioning to help investors determine which vehicle better aligns with their objectives in the current market environment.
IXJ is a passively managed fund that seeks to track the S&P Global 1200 Health Care (Sector) Capped Index, a market-capitalization-weighted benchmark of large- and mid-cap healthcare companies across global developed markets. The fund holds roughly 130 securities, spanning pharmaceutical, biotechnology, medical device, healthcare equipment, and managed care names. Its top holdings include LLY, JNJ, ABBV, MRK, and UNH, alongside large European constituents such as Roche, Novartis, and AstraZeneca. Geographically, the portfolio is heavily weighted to North America (roughly 75%) with a meaningful European allocation. The fund carries a net expense ratio of approximately 0.38% and rebalances according to its underlying index. Its defining feature is breadth: investors gain diversified access to virtually every corner of the global healthcare value chain rather than a single subsector. I also checked this using Tickeron’s AI Screener to see how the holdings compare to peers.
PPH is a passively managed fund that seeks to replicate the MVIS US Listed Pharmaceutical 25 Index, a benchmark of U.S. exchange-listed pharmaceutical companies, including foreign issuers trading as ADRs. With only 25 to 26 holdings, the fund is classified as non-diversified, meaning a small number of names drive a large share of performance. LLY dominates at roughly 20% of assets, followed by MRK, NVO, PFE, and BMY, with additional weight in NVS, GSK, MCK, and COR. Notably, the index includes drug distributors and generic manufacturers, so it is not a pure branded-pharma play. The fund's expense ratio is 0.36%. Its structural profile is concentrated and high-conviction, making it more sensitive to the earnings cycles of its largest constituents.
Both funds operate within a healthcare landscape shaped by powerful, multi-year forces. The obesity and metabolic-disease market, led by GLP-1 drugmakers such as LLY and NVO, has driven substantial capital flows into pharmaceutical names. Innovation in oncology, immunology, and gene therapy continues to support pipeline momentum, while patent expirations on legacy blockbusters create earnings volatility for individual companies. Regulatory scrutiny over drug pricing, insurance coverage of weight-loss medications, and merger-and-acquisition activity also influence sentiment. From a macroeconomic perspective, healthcare is often viewed as a defensive, non-cyclical allocation that can hold up when growth sectors falter, though rising interest rates can pressure valuations of high-growth biotech. These catalysts affect the broader healthcare universe captured by IXJ more evenly than the concentrated pharmaceutical exposure in PPH.
In recent market cycles, the two funds have diverged in line with their structural differences. PPH has been more volatile and more levered to the performance of a handful of large-cap drugmakers, meaning its fund performance has amplified both the upside from GLP-1-driven momentum and the downside from individual stock setbacks. IXJ, by contrast, has delivered more balanced relative positioning, with its medical device, managed care, and diversified pharmaceutical sleeves offsetting weakness in any single subsector. Broader sector rotation, earnings cycles of top holdings, and shifts in interest rate expectations have affected both funds, but IXJ's wider net typically translates into lower single-name risk. Investors seeking pure pharmaceutical beta have favored PPH, while those prioritizing diversification across the full healthcare economy have gravitated toward IXJ. From what I see, the divergence underscores the importance of matching the fund to specific risk tolerance.
Weighing structural strength, cost efficiency, diversification profile, trend consistency, and risk exposure, Tickeron's AI would currently favor IXJ over PPH. While PPH offers slightly lower fees and a purer, higher-conviction pharmaceutical tilt, its non-diversified construction concentrates roughly 20% of assets in a single issuer, elevating idiosyncratic risk. IXJ's broader subsector and geographic footprint, comparable cost, and lower single-name sensitivity give it a more balanced risk-adjusted profile across recent market cycles. The AI's preference reflects a probabilistic assessment of relative positioning rather than a guarantee of future returns, and it may shift as sector momentum and constituent earnings evolve. I’m watching this closely as sector dynamics continue to shift.
In my own analysis of sector ETFs, Tickeron’s AI Screener has proven useful for quickly filtering holdings, comparing concentrations, and spotting patterns across healthcare names. It helps surface relevant data on volatility, trends, and benchmarks without manual effort, which streamlines the process when evaluating options like these two funds.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 10-day moving average for IXJ crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on IXJ as a result. In 66 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
IXJ moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where IXJ advanced for three days, in 256 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 218 of 263 cases where IXJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The 10-day RSI Indicator for IXJ moved out of overbought territory on November 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 27 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 68 cases where IXJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for IXJ turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 38 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IXJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
IXJ broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows